2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5743 The double dip: Identifying Critical Time Points for cytopenia after bispecific antibody therapy

Kristina Nasr, MD, Rafaella Litvin, MD2, Ran Zhao3, Agrima Mian, MD4, Mikhaila Rice, PharmD5, Joslyn Rudoni6, Allison Winter, MD7, Deepa Jagadeesh, MD, MPH8, Robert Dean, MD9, Taylor R. Brooks, MD10, Louis Samuel Williams, MD11, Shahzad Raza, MD12, Faiz Anwer, MD13, Jason Valent, MD14, Christy Samaras, DO15, Kelsey Pandrangi, MD16, John Carlos Molina, MD, MEd17, Claudio Brunstein, MD, PhD18, Sharan Jhaveri, MD19, Evandro Bezerra, MD20, Diana Basali, MD21, Sandra Mazzoni, DO22, Brian Hill, MD, PhD23, Jack Khouri, MD24, Paolo Fabrizio Caimi, MD25
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States
17 Cleveland Clinic Foundation, Cleveland, Ohio, United States
18 Cleveland Clinic Foundation, Cleveland, Ohio, United States
19 Cleveland Clinic Foundation, Cleveland, Ohio, United States
20 The Ohio State University, colombus, Ohio, United States
21 Cleveland Clinic Foundation, Cleveland, Ohio, United States
22 Cleveland Clinic Foundation, Cleveland, Ohio, United States
23 Cleveland Clinic Foundation, Cleveland, Ohio, United States
24 Cleveland Clinic Foundation, Cleveland, Ohio, United States
25 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction: Bispecific T-cell–engaging antibodies (BsAbs) are cornerstone therapies for relapsed/refractory multiple myeloma and non-Hodgkin lymphoma (NHL) but cause substantial hematologic toxicity. Cytopenia can disrupt treatment delivery and adversely affect outcomes. We evaluated longitudinal cytopenia trends and compared trajectories between low- and high-risk groups defined using our clinical cytopenia risk score. 

Methods: We collected data on 140 patients with MM or NHL treated with BsAbs between 2020 and 2024 who developed cytopenia. Cytopenia was defined as grade ≥3 anemia (Hb <8 g/dL), grade ≥3 thrombocytopenia (platelet count <50 × 10⁹/L), or any-grade neutropenia (ANC <1.5 × 10⁹/L) occurring during BsAb therapy or within 90 days after treatment discontinuation. Patients were followed until last follow-up, disease progression, initiation of subsequent therapy, or death. Longitudinal ANC, Hb, and platelet values were collected from BsAb initiation through day 130 when applicable. For the overall cohort, the median of all available values was calculated at each time point and plotted against time. LOESS curves with confidence bands were fitted to the median values to visualize trends over time on a scatter plot. Patients were then stratified into low- and high-risk groups using our previously developed clinical cytopenia risk score. Described separately, this point-based model uses baseline ANC, Hb, and platelet counts to predict cytopenia risk, with an AUC of 0.893. Within each risk group, median values were calculated at each time point and plotted against time. The association between each hematologic parameter and time was evaluated using Spearman rank correlation. 

Results: Among 140 patients, 107 had MM and 33 NHL. At BsAb initiation, median Hb, platelets, and ANC were 9.5 g/dL, 132.5 × 10⁹/L, and 2.61 × 10⁹/L, respectively. During follow-up, persistent anemia was observed in 80 patients (57%), persistent thrombocytopenia in 64 (46%), and persistent neutropenia in 114 (81%). Median neutropenia duration was 29 days; 46 reached an ANC nadir <0.5 × 10⁹/L, including 11with the neutropenia lasting >7 days. Infections occurred in 83 patients, including 41 with grade ≥3. Twenty-three patients discontinued treatment because of toxicity without disease progression. Both ANC and platelets had a double dip pattern characterized by an initial decrease (ANC nadir day 20, platelet nadir day 35), followed by a first increase (ANC peak on day 60, platelet peak day 65), a second decrease (ANC and platelet nadir on day 90), and then a subsequent second continued improvement. Hemoglobin remained relatively stable early on, increased through approximately day 65, then modestly declined or plateaued around days 70–80 before rising steadily through follow-up. When stratified by risk groups, low-risk patients (n = 18) started with higher counts, followed by a marked decline around day 30 and steady recovery throughout follow-up. High-risk patients (n = 122) started with lower counts and experienced the described “double dip” trajectory of ANC and platelet counts. 

Conclusion:
 ANC and platelet counts demonstrated biphasic “double-dip” trajectories, with early declines after BsAb initiation and a second decline around days 90–100, whereas Hb showed a gradual recovery after initial decrease without a second decline. These findings identify clinically relevant time points when heightened surveillance for cytopenia is warranted. Risk-stratified trajectories may further help identify patients who could benefit from intensified monitoring and preemptive supportive strategies, including prophylactic G-CSF, to reduce treatment interruptions. 

Kristina Nasr, MD: No relevant conflicts of interest to declare.